Daniel Weigner’s Post

We were delighted to welcome Shield Therapeutics plc to present at the Hardman & Co Investor Forum, outlining their ambitious expansion plans and the significant growth of their flagship product, Accrufer. Management emphasised its commitment to navigating the challenges associated with scaling up operations and ensuring long-term value creation, focusing on achieving cash flow positivity. Watch Shield Therapeutics' presentation here -  https://lnkd.in/e6ceNzmZ #pharmacueticals #medical #investments #investors #capitalmarkets

Versant Ventures Unveils Pep2Tango Therapeutics Inc. https://lnkd.in/eTDbAD5z. Versant Ventures Pep2Tango Therapeutics Cristina Rondinone Soumitra Ghosh, Ph.D. Carlo Rizzuto Steven Edelson More US life science business news at [LSUS] Life-Sciences-USA.com __

Discover how Pega is driving innovation for global leaders like Prime Therapeutics. Jillian Lucas, SVP of Process and Program Excellence, shares how Pega has reduced turnaround times and cut inefficiencies, enabling teams to focus on impactful, human-centered work.

Nuvig Therapeutics Announces $161m Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator https://lnkd.in/gxhqHG_v Nuvig Therapeutics Inc. Sanofi Ventures Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments Norwest Venture Partners Leaps by Bayer Global BioAccess Fund LOTTE Holdings Alexandria Venture Investments abrdn Novo Holdings Platanus Bristol Myers Squibb Digitalis Ventures Mission BioCapital Pamela Conley Paulina Hill Tim Anderson Tiba Aynechi More Transatlantic life science business news at [LSUS] Life-Sciences-USA.com __

Antag Therapeutics Announces €80m Series A Financing Led by Versant Ventures https://lnkd.in/eNPGa7ZM Antag Therapeutics Alexander Sparre-Ulrich Versant Ventures Alexander Mayweg Novo Holdings Jeroen Bakker SR One Capital Management Dawn Biopharma Pictet Group More European life science business news at [LSE] Life-Sciences-Europe.com __

Antag Therapeutics raises €80 Million Series A to enter Phase I for its next-generation weight loss therapy https://lnkd.in/d8SR3C8p #obesity #pharmaindustry #therapeutics Antag Therapeutics Versant Ventures Novo Holdings Novo Holding Novo Nordisk SR One Capital Management Dawn Biopharma Pictet Group Longview Ventures Alexander Sparre-Ulrich Alexander Mayweg Jeroen Bakker

BGV (BioGeneration Ventures) portfolio company Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the closing of a EUR 60M Series B financing. The round was led by Ackermans & van Haaren (AvH) and included participation from additional new investors, Driehaus Capital Management LLC and Quest for Growth (QfG), as well as existing investors, BGV (BioGeneration Ventures), CAPRICORN HEALTH-TECH FUND (CHF), Fund+, MINTS (University of Michigan), Perceptive Advisors, Qbic Fund | Venture Capital, PMV, V-Bio Ventures, VIB and Wellington Partners. The proceeds will be used to advance two, wholly owned programs through Phase 1 and two additional programs to IND approval, including molecules targeting GPR75 for obesity. Confo will expand its portfolio of GPCR-targeting small molecules and therapeutic antibodies, which includes an emphasis on agonistic antibodies. #seriesB #financing #lifesciences #biotech Edward Van Wezel Diede Brunen

As TRexBio accelerates to the clinic with its first internal program for immune-mediated diseases, congratulations to the “dream team” — Carol Gallagher, Johnston Erwin, Laura Berner, Melanie Kleinschek, Ali Zarrin — on an incredible raise! Their achievement is truly something to be proud of. From humble beginnings in a one-room sublease at Mitten Road in Burlingame, early science strongly pointed to the fact that when immune cells traffic to the tissue, their phenotype changes to adapt to the tissue microenvironment. This tissue phenotype of immune cells is very different from their phenotype in circulation. TRexBio’s, outlines in the press release, its observation that TNFR2 is highly expressed on the most suppressive regulatory T cells (“Tregs”) in skin and gut. TRB-061 is designed to selectively agonize TNFR2, activating tissue-licensed Tregs to address a range of inflammatory and autoimmune conditions. These tissue-licensed Tregs may provide an enhanced therapeutic index and site-specific action. TRexBio is poised to test this therapeutic hypothesis in the clinic with TRB-061 for immune-mediated diseases. I am excited to see the clinical data from TRB-061 and all the TRexBio programs! "The tissue is the issue" #TissueResidentTregs #I&I #immunology #autoimmunity #patientcare #inflammation #companycreation #innovation #biotech #drugdevelopment #teentregomiinspiración https://lnkd.in/g5dSj5ia

To read the full report, click on the link in the original post comments 

On Tuesday we announced our first quarter 2024 financial results. On the earnings call, CEO Todd Davis, and members of the Ligand senior management team, highlighted our positive momentum during the first quarter, the significant progress of our commercial and development stage portfolio including our recent #royaltyfinancing agreement with Agenus and the launch of Pelthos Therapeutics, and the key growth drivers for the remainder of the year. View our earnings release here: https://bit.ly/4acV1D5